Related Experiment Videos
Nursing care of the neonate receiving prostaglandin E1 therapy
Insights
Prostaglandin E1 (PGE1) is crucial for neonates with congenital heart disease, maintaining ductal patency for survival. Prompt therapy with PGE1 allows stabilization for surgery or heart transplantation.
Area of Science:
- Neonatal Cardiology
- Pediatric Intensive Care
- Pharmacology
Background:
- Prostaglandin E1 (PGE1) approved in 1981 by the FDA for neonates with congenital heart disease.
- PGE1 maintains ductus arteriosus patency in ductal-dependent cardiac lesions, critical for systemic or pulmonary blood flow.
- Early recognition and prompt PGE1 therapy are vital for survival in neonates with ductal-dependent cardiac lesions.
Purpose of the Study:
- To highlight the critical role of PGE1 in managing neonates with congenital heart disease.
- To emphasize the importance of timely PGE1 administration for hemodynamic stability.
- To inform healthcare providers about PGE1's applications and side effects.
Main Methods:
- PGE1 administration for maintaining ductus arteriosus patency.
- Continuous intravenous infusion for consistent therapeutic levels.
- Monitoring for potential side effects.
Main Results:
- PGE1 facilitates stabilization, allowing delayed surgery or transfer to tertiary care.
- It serves as a bridge to heart transplantation in eligible neonates.
- Effective management of cyanotic and acyanotic heart conditions requiring ductal support.
Conclusions:
- PGE1 is essential for managing neonates with ductal-dependent congenital heart disease.
- Continuous infusion and vigilant monitoring for side effects are necessary.
- Knowledge of PGE1's side effects is crucial for nursing care.
Abstract:
In 1981, the Food and Drug Administration approved prostaglandin E1 (PGE1) for use in the treatment of neonates with congenital heart disease. PGE1 is commonly used in neonatal and pediatric intensive care units to maintain patency of the ductus arteriosus in those cardiac lesions that depend on the ductus for either systemic or pulmonary blood flow. Early recognition of hemodynamic instability and prompt initiation of PGE1 therapy is vital to survival in neonates with ductal-dependent cardiac lesions. Administration of PGE1 allows delay of palliative or corrective surgery until stabilization or transfer of the neonate to a tertiary care facility is achieved. It is also used as a bridge to heart transplantation in neonates in whom this treatment is an option. Congenital anomalies requiring treatment with PGE1 are those that restrict pulmonary blood flow (cyanotic or right-sided outflow tract obstructions) and systemic blood flow (acyanotic or left-sided outflow tract obstructions). Prostaglandin E1 is excreted by the kidneys, and elimination is almost complete within 24 hours after administration; 80 percent of it is rapidly metabolized after one pass through the pulmonary bed. Therefore, a continuous infusion and adequate intravenous access are necessary. Nurses caring for these neonates must have knowledge of all its potential side effects. Some of the most common side effects include cutaneous vasodilation, bradycardia, tachycardia, hypotension, seizure-like activity, hyperthermia, and apnea.